1. US Department of Health and Human Services, Food and Drug Administration. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products [online] , (2004). This White Paper written by the US FDA details a regulatory initiative to facilitate the translation of medical products to improved health.
2. US Department of Health and Human Services, Food and Drug Administration. Critical Path Opportunities Report [online] , (2006). This report written by the US FDA, in collaboration with a range of stakeholders, identifies six key areas where focused research has great potential to stimulate product development. An accompanying list of research projects, the 'Critical Path Opportunities List', is also available at http://www.fda.gov/oc/initiatives/criticalpath/reports/opp_list.pdf .
3. AdvaMed. AdvaMed's submitted comments on FDA's Critical Path Intitiative [online] , (2004).
4. Tsongalis, G. J. A reality check for molecular diagnostics in clinical practice. Pharmacogenomics 4, 667–668 (2003).
5. Woodcock, J. The Critical Path: One Year Later. Presentation at the FDA/DIA/BIO Meeting: Use of Medical Imaging as a Drug Development Tool [online] , (2005).